ARCHIVES

FDA Committee Agenda Includes M-AMSA, THC, Estramustine, Platinum

This article is from The Cancer Letter archive.

Vol. 07 No. 21 | May 22, 1981

Download PDF Visit The Full Archive

Related Articles

NCI Plans SBIR “Bridge” Award To Commercialize Technology.

April 11, 2008

NCI Ponders Options for Implementing NCAB Changes In Organ Site Program

June 4, 1982

“You Can’t Legislate Biology,” Higginson Tells AACI Members

February 9, 1979

In Brief: Durant To Retire From ASCO In A Year; Led Society Through Management Change

July 24, 1998

ADT May Increase Risk Of Cardio Events In Prostate Cancer Patients

February 5, 2010

Shubik Subcommittee Fails To Agree On Draft Document

February 13, 1976